A Conversation on Combination Therapy, Safety Profiles, and Targeted IL-17 Systemic Treatments

The experts discuss combination therapy approaches, safety considerations, and targeted interleukin-17 systemic treatments for plaque psoriasis.

EP: 1.Navigating Plaque Psoriasis: Insights into the Psychosocial Impact and Evolving Treatment Landscape

EP: 2.Plaque Psoriasis Case Study: Patient Presentation, Treatment Selection, and Shared Decision-Making for Improved Outcomes

EP: 3.Empowering Patients with Plaque Psoriasis: Navigating Treatment Challenges Informed Patient Conversations and Decision Trees

Now Viewing

EP: 4.A Conversation on Combination Therapy, Safety Profiles, and Targeted IL-17 Systemic Treatments

EP: 5.Clinical Insights: Managing Psoriasis Treatment Dynamics and Strategic Therapy Switching Considerations

EP: 6.Head-to-Head Clinical Trials: Comparing Psoriasis Treatment Response Rates

EP: 7.TYK2 Inhibition and Deucravacitinib: Mechanism of Action, Safety Considerations, and Patient-Provider Conversations

EP: 8.Comparative Analysis: Deucravacitinib and Adalimumab in Psoriasis Treatment

EP: 9.Understanding IL-17 Therapies: Treatment Considerations, Rapid Response, and Impact on Plaque Psoriasis Location

EP: 10.Expert Insights into Managing Inadequate Response to Systemic Therapies: Strategies and Solutions

EP: 11.Long-Term Efficacy and Insights from POETYK PSO-1 Studies: Implications for Psoriasis Treatment

EP: 12.Achieving Durable Responses: Physician's Guide to Interpreting Long-Term Efficacy Data

EP: 13.When to Discontinue Treatment: Interpreting Safety Signals and Adverse Event Patterns

EP: 14.Updating Treatment Guidelines: Incorporating Novel Therapies to Address Unmet Needs

EP: 15.Available Psoriasis, Patient Involvement, and Holistic Treatment

Related Videos

Related Content

Advertisement

March 12th 2025

Robert Bissonnette, MD: Late-Breaking Data on Icotrokinra Shows Promising Efficacy and Safety in Psoriasis

November 4th 2021

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

March 11th 2025

Icotrokinra Demonstrates Promise in Phase 3 ICONIC-LEAD and ICONIC-ADVANCE for Plaque Psoriasis

September 23rd 2021

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

March 10th 2025

Biologic-Naïve Patients with Psoriasis Have a Reduced Risk of Psoriatic Arthritis, Based on NPF Target Goals

March 9th 2025

Risankizumab Maintains High Skin Clearance Over 36 Months

Related Content

Advertisement

March 12th 2025

Robert Bissonnette, MD: Late-Breaking Data on Icotrokinra Shows Promising Efficacy and Safety in Psoriasis

November 4th 2021

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

March 11th 2025

Icotrokinra Demonstrates Promise in Phase 3 ICONIC-LEAD and ICONIC-ADVANCE for Plaque Psoriasis

September 23rd 2021

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

March 10th 2025

Biologic-Naïve Patients with Psoriasis Have a Reduced Risk of Psoriatic Arthritis, Based on NPF Target Goals

March 9th 2025

Risankizumab Maintains High Skin Clearance Over 36 Months